Key result
LDLR deficiency and PCSK9 treatment substantially reduce hepatocyte uptake and blood clearance of LPS.
Demonstrates that hepatocytes clear circulating lipopolysaccharide via the low-density lipoprotein receptor, indicating how PCSK9 inhibition protects against sepsis.
Sepsis is the leading cause of death in critically ill patients. While decreased Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) function improves clinical outcomes in murine and human sepsis, the mechanisms involved have not been fully elucidated. We tested the hypothesis that lipopolysaccharide (LPS), the major Gram-negative bacteria endotoxin, is cleared from the circulation by hepatocyte Low Density Lipoprotein Receptors (LDLR)-receptors downregulated by PCSK9. We directly visualized LPS uptake and found that LPS is rapidly taken up by hepatocytes into the cell periphery. Over the course of 4 hours LPS is transported towards the cell center. We next found that clearance of injected LPS from the blood was reduced substantially in Ldlr knockout (Ldlr-/-) mice compared to wild type controls and, simultaneously, hepatic uptake of LPS was also reduced in Ldlr-/- mice. Specifically examining the role of hepatocytes, we further found that primary hepatocytes isolated from Ldlr-/- mice had greatly decreased LPS uptake. In the HepG2 immortalized human hepatocyte cell line, LDLR silencing similarly resulted in decreased LPS uptake. PCSK9 treatment reduces LDLR density on hepatocytes and, therefore, was another independent strategy to test our hypothesis. Incubation with PCSK9 reduced LPS uptake by hepatocytes. Taken together, these findings demonstrate that hepatocytes clear LPS from the circulation via the LDLR and PCSK9 regulates LPS clearance from the circulation during sepsis by downregulation of hepatic LDLR.
No takes yet. Share an insight, caveat, or question.
Topchiy et al. (2016) studied Sepsis / Lipopolysaccharide (LPS) endotoxemia. LDLR knockout, LDLR silencing, or PCSK9 incubation vs. Wild-type controls / untreated hepatocytes was evaluated on Hepatocyte uptake and circulatory clearance of lipopolysaccharide (LPS). LDLR knockout, LDLR silencing, and PCSK9 treatment substantially reduced hepatocyte uptake and blood clearance of LPS over 4 hours compared with controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: